1. Home
  2. NSTS vs RLYB Comparison

NSTS vs RLYB Comparison

Compare NSTS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NSTS Bancorp Inc.

NSTS

NSTS Bancorp Inc.

HOLD

Current Price

$14.15

Market Cap

73.9M

Sector

Finance

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$16.86

Market Cap

89.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSTS
RLYB
Founded
1921
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.9M
89.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
NSTS
RLYB
Price
$14.15
$16.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.4K
7.4K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
6.16
Revenue
$252,000.00
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.75
Revenue Growth
N/A
43.00
52 Week Low
$10.73
$0.48
52 Week High
$14.19
$17.57

Technical Indicators

Market Signals
Indicator
NSTS
RLYB
Relative Strength Index (RSI) 71.30 N/A
Support Level $13.70 N/A
Resistance Level $14.19 N/A
Average True Range (ATR) 0.05 0.00
MACD -0.00 0.00
Stochastic Oscillator 85.00 0.00

Price Performance

Historical Comparison
NSTS
RLYB

About NSTS NSTS Bancorp Inc.

NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: